Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG447)
Fast, easy summary view of NICE guidance on 'acutely ill patients in hospital'
The Interventional Procedures Advisory Committee (IPAC) has considered this procedure and NICE has issued a consultation document about its safety and efficacy. Consultation has now ended. IPAC will consider the consultation comments and produce a Final Interventional Procedures Document, which will be considered by NICE before guidance is issued to the NHS in England, Wales, Scotland and Northern Ireland.
The consultation period for this procedure closed on the 20th September 2013.
If you wish to be alerted to developments regarding this procedure, including the release of NICE guidance, please express your interest at the top of the page.
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common types of skin cancer. They are generally slow-growing but can cause extensive tissue destruction if not treated, and SCC can spread to other parts of the body.
In electrochemotherapy an anticancer drug is given by injection either into a vein or directly into a tumour. Short, powerful pulses of electricity are then applied to the tumour. The electrical energy opens the membranes (outer coverings) of the tumour cells, allowing the anticancer drug to pass through into the cells and have a more damaging effect.
There is no specific code in OPCS-4 for electrochemotherapy and only the chemotherapy part of the procedure is classifiable in OPCS-4. The chemotherapy part of the procedure would be recorded using the codes that classify the type of chemotherapy that has been delivered. It is not currently possible to identify that electric pulses were delivered to the tumour cells following administration of the chemotherapy drugs using OPCS-4 codes.
The NHS Classifications Service of NHS Connecting for Health is the central definitive source for clinical coding guidance and determines the coding standards associated with the classifications (OPCS-4 and ICD-10) to be used across the NHS. The NHS Classifications Service and NICE work collaboratively to ensure the most appropriate classification codes are provided. www.connectingforhealth.co.uk/clinicalcoding)
- Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma: consultation document - 2nd consultation
- IP/1017 Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma: consultation comments table 1st consultation
- IPG447 Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma: equality impact assessment
- Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma: consultation document - 1st consultation
- Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma: overview
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: acutely ill patients in hospital
This page was last updated: 04 October 2013
- Web format
- Full Guidance (PDF)
- IPG447 Trin carsinoma celloedd gwaelodol sylfaenol a charsinoma celloedd cennog sylfaenol gan ddefnyddio cemotherapi â churiadau trydanol - Gwybodaeth i'r cyhoedd (fformat MS Word)
Information for the public
Implementation tools and resources
- None available
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.